Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Tocagen to host conference call » 05:24
02/20/20
02/20
05:24
02/20/20
05:24
TOCA

Tocagen

$0.49 /

-0.0596 (-10.94%)

Conference call to…

Conference call to discuss agreement to merge with Forte Biosciences, Inc. will be held on February 20 at 8:30 am. Webcast Link

ShowHide Related Items >><<
TOCA Tocagen
$0.49 /

-0.0596 (-10.94%)

09/13/19 Citi
Tocagen downgraded to Neutral from Buy at Citi
09/13/19 Chardan
Tocagen downgraded to Neutral from Buy at Chardan
09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
Hot Stocks
Tocagen, Forte Biosciences to merge » 20:14
02/19/20
02/19
20:14
02/19/20
20:14
TOCA

Tocagen

$0.49 /

-0.0596 (-10.94%)

Tocagen and Forte…

Tocagen and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX. Forte's lead asset, FB-401, is a potentially first-in-class, live biotherapeutic being developed as a topical therapy for the treatment of inflammatory skin diseases, including atopic dermatitis. In a Phase 1/2a trial in adults and pediatrics, FB-401 demonstrated significant efficacy and a favorable safety and tolerability profile. The full trial results will be submitted for publication in a peer-reviewed journal in the first half of 2020. A randomized Phase 2 trial is planned to commence in mid-2020 in adults and pediatrics with atopic dermatitis, providing an expected data readout in mid-2021.

ShowHide Related Items >><<
TOCA Tocagen
$0.49 /

-0.0596 (-10.94%)

09/13/19 Citi
Tocagen downgraded to Neutral from Buy at Citi
09/13/19 Chardan
Tocagen downgraded to Neutral from Buy at Chardan
09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
Hot Stocks
Tocagen says Phase 3 trial did not meet primary, secondary endpoints » 16:08
11/22/19
11/22
16:08
11/22/19
16:08
TOCA

Tocagen

$0.74 /

+0.1121 (+17.94%)

Tocagen announced…

Tocagen announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma at the Society for Neuro-Oncology Annual Meeting. The data were presented on behalf of the Toca 5 clinical investigators by Timothy Cloughesy, M.D., professor of neurology and director of the neuro-oncology program at the University of California, Los Angeles and principal investigator for the Toca 5 trial. The trial did not meet the primary or secondary endpoints. The safety, tolerability and adverse event profile of Toca 511 & Toca FC was as expected for this patient population. "The positive outcome for patients at second recurrence in the Toca 5 trial are compelling, despite the disappointment of the overall trial results," said Dr. Cloughesy. "Combined with an acceptable safety profile, these data support a potential opportunity to address the high unmet needs of this well-defined patient population and should inform any future development of the Toca 511 & Toca FC regimen."

ShowHide Related Items >><<
TOCA Tocagen
$0.74 /

+0.1121 (+17.94%)

09/13/19 Citi
Tocagen downgraded to Neutral from Buy at Citi
09/13/19 Chardan
Tocagen downgraded to Neutral from Buy at Chardan
09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
Earnings
Tocagen reports Q3 EPS (78c), consensus (70c) » 16:33
11/12/19
11/12
16:33
11/12/19
16:33
TOCA

Tocagen

$0.65 /

+0.0212 (+3.40%)

License revenue was less…

License revenue was less than $0.1M for the quarter ended September 30, compared to $18M for the quarter ended September 30, 2018. The 2018 revenue was related to upfront payments and milestones earned under our license agreement with Apollobio. Q3 revenue consensus $500,000.

ShowHide Related Items >><<
TOCA Tocagen
$0.65 /

+0.0212 (+3.40%)

09/13/19 Citi
Tocagen downgraded to Neutral from Buy at Citi
09/13/19 Chardan
Tocagen downgraded to Neutral from Buy at Chardan
09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
Hot Stocks
Tocagen announces restructuring, to reduce workforce by about 65% » 08:01
10/03/19
10/03
08:01
10/03/19
08:01
TOCA

Tocagen

$0.58 /

-0.034 (-5.54%)

Tocagen announced a…

Tocagen announced a restructuring to focus its resources on the clinical development of Toca 511 and Toca FC. Tocagen will reduce its workforce by approximately 65%, resulting in an estimated 30 remaining full-time employees by the end of the year. The company plans to provide financial guidance in the fourth quarter.

ShowHide Related Items >><<
TOCA Tocagen
$0.58 /

-0.034 (-5.54%)

09/13/19 Citi
Tocagen downgraded to Neutral from Buy at Citi
09/13/19 Chardan
Tocagen downgraded to Neutral from Buy at Chardan
09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
Downgrade
Tocagen downgraded to Neutral from Buy at Citi » 05:10
09/13/19
09/13
05:10
09/13/19
05:10
TOCA

Tocagen

$0.93 /

-3.2223 (-77.55%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal downgraded Mohit Bansal to Neutral from Buy and cut his price target for the shares to $1 from $20. The failure of TOCA 5 could make investors question Tocagen's platform and future given that most of its pipeline relies on the same technology, Bansal tells investors in a research note. With management conducting a business review to chart out the future direction for the company, the analyst moves to the sidelines pending more clarity on a future direction.

ShowHide Related Items >><<
TOCA Tocagen
$0.93 /

-3.2223 (-77.55%)

09/13/19 Chardan
Tocagen downgraded to Neutral from Buy at Chardan
09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
09/12/19 Evercore ISI
Tocagen downgraded to In Line from Outperform at Evercore ISI
Downgrade
Tocagen downgraded to Neutral from Buy at Chardan » 05:08
09/13/19
09/13
05:08
09/13/19
05:08
TOCA

Tocagen

$0.93 /

-3.2223 (-77.55%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits downgraded Tocagen to Neutral from Buy with a price target of $1, down from $10, after the company announced its pivotal Phase III trial in recurrent high grade glioma missed primary and secondary endpoints. The analyst sees limited pipeline visibility for Tocagen.

ShowHide Related Items >><<
TOCA Tocagen
$0.93 /

-3.2223 (-77.55%)

09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
09/12/19 Evercore ISI
Tocagen downgraded to In Line from Outperform at Evercore ISI
09/12/19 H.C. Wainwright
H.C. Wainwright downgrades Tocagen with no target after 'major setback'
On The Fly
Fly Intel: Wall Street's top stories for Thursday » 16:24
09/12/19
09/12
16:24
09/12/19
16:24
ORCL

Oracle

$53.91 /

-2.54 (-4.50%)

, T

AT&T

$38.36 /

-0.53 (-1.36%)

, GOOG

Alphabet

$1,234.00 /

+13.83 (+1.13%)

, GOOGL

Alphabet Class A

$1,235.26 /

+15.3 (+1.25%)

, ENPH

Enphase Energy

$22.20 /

-2.52 (-10.19%)

, SEDG

SolarEdge

$71.64 /

-7.78 (-9.80%)

, MRNA

Moderna

$16.38 /

+0.48 (+3.02%)

, LKQ

LKQ Corp.

$32.55 /

+3.49 (+12.01%)

, TOCA

Tocagen

$0.93 /

-3.2233 (-77.58%)

, GRPN

Groupon

$2.89 /

-0.13 (-4.31%)

, YELP

Yelp

$36.54 /

+0.69 (+1.92%)

Stocks climbed during…

Open Full Text

ShowHide Related Items >><<
ORCL Oracle
$53.91 /

-2.54 (-4.50%)

09/12/19 Morgan Stanley
Oracle continues struggling for growth, says Morgan Stanley
09/12/19 Barclays
Oracle shares will likely remain range-bound, says Barclays
09/12/19 BMO Capital
Oracle price target raised to $60 after Q1 results, says BMO Capital
09/12/19 Nomura Instinet
Oracle results do not alter bearish thesis, says Nomura Instinet
T AT&T
$38.36 /

-0.53 (-1.36%)

09/11/19 Credit Suisse
Netflix head start unlikely dented by Apple TV+, says Credit Suisse
09/11/19 Wells Fargo
Apple focusing on presenting iPhone Pro as premium product, says Wells Fargo
09/10/19 Oppenheimer
Elliot's plan to accelerate AT&T shareowner value, says Oppenheimer
09/10/19 Barclays
AT&T price target raised to $35 from $31 at Barclays
GOOG Alphabet
$1,234.00 /

+13.83 (+1.13%)

09/10/19 Credit Suisse
Netflix Q3 app downloads rebounding, says Credit Suisse
09/06/19 BofA
BofA says Google ad product pipeline has potential to accelerate 2020 growth
09/05/19 Craig-Hallum
Craig-Hallum cuts TeleNav to Hold as GM transitions to Google Maps
09/05/19
Nutanix a 'strong acquisition candidate' for Google, says Trefis
GOOGL Alphabet Class A
$1,235.26 /

+15.3 (+1.25%)

ENPH Enphase Energy
$22.20 /

-2.52 (-10.19%)

09/12/19 Roth Capital
Generac success against Enphase, SolarEdge not guaranteed, says Roth Capital
08/26/19 Northland
Enphase Energy price target raised to $40 from $28 at Northland
08/07/19 Oppenheimer
SolarEdge price target raised to $78 from $66 at Oppenheimer
07/31/19 Craig-Hallum
Enphase Energy price target raised to $31 from $25 at Craig-Hallum
SEDG SolarEdge
$71.64 /

-7.78 (-9.80%)

08/22/19 UBS
SolarEdge downgraded to Neutral at UBS, price target raised to $90
08/22/19 UBS
SolarEdge downgraded to Neutral from Buy at UBS
08/13/19 JPMorgan
SolarEdge price target raised to $100 from $84 at JPMorgan
MRNA Moderna
$16.38 /

+0.48 (+3.02%)

08/16/19 Piper Sandler
Moderna should be bought ahead of catalysts, says Piper Jaffray
07/24/19 Morgan Stanley
Warming could create need for up to $125B more vaccinations, says Morgan Stanley
06/20/19 Piper Sandler
Moderna recent weakness a buying opportunity, says Piper Jaffray
05/29/19 Oppenheimer
Moderna price target raised to $31 from $27 at Oppenheimer
LKQ LKQ Corp.
$32.55 /

+3.49 (+12.01%)

08/14/19
LKQ Corp.management to meet with Stephens
08/13/19
LKQ Corp.management to meet with Stephens
07/26/19 Raymond James
Raymond James sees execution risk at LKQ, downgrades to Market Perform
07/26/19 Raymond James
LKQ Corp. downgraded to Market Perform from Outperform at Raymond James
TOCA Tocagen
$0.93 /

-3.2233 (-77.58%)

09/12/19 B. Riley FBR
Tocagen downgraded to Neutral from Buy at B. Riley FBR
09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
09/12/19 Evercore ISI
Tocagen downgraded to In Line from Outperform at Evercore ISI
09/12/19 H.C. Wainwright
H.C. Wainwright downgrades Tocagen with no target after 'major setback'
GRPN Groupon
$2.89 /

-0.13 (-4.31%)

02/04/19
Fly Intel: Top five analyst initiations
02/04/19 Goldman Sachs
Groupon initiated with a Neutral at Goldman Sachs
09/14/18 DA Davidson
Groupon is 'attractively priced', says DA Davidson
09/14/18 Wedbush
Groupon initiated with a Neutral at Wedbush
YELP Yelp
$36.54 /

+0.69 (+1.92%)

08/09/19 DA Davidson
Yelp CFO departure another indication of possible sale, says DA Davidson
06/04/19 Aegis
Yelp upgraded to Hold from Sell at Aegis
05/10/19 B. Riley FBR
Yelp downgraded to Neutral on declining pricing visibility at B Riley FBR
05/10/19 B. Riley FBR
Yelp downgraded to Neutral from Buy at B. Riley FBR
Downgrade
Tocagen downgraded to Neutral from Buy at B. Riley FBR » 13:23
09/12/19
09/12
13:23
09/12/19
13:23
TOCA

Tocagen

$0.98 /

-3.175 (-76.41%)

B. Riley FBR analyst…

B. Riley FBR analyst George Zavoico downgraded Tocagen to Neutral from Buy with a $1 price target after the company said the Phase 3 pivotal Toca 5 study for the treatment of recurrent high-grade gliomas missed the primary endpoint of overall survival.

ShowHide Related Items >><<
TOCA Tocagen
$0.98 /

-3.175 (-76.41%)

09/12/19 Ladenburg
Tocagen downgraded to Neutral from Buy at Ladenburg
09/12/19 Evercore ISI
Tocagen downgraded to In Line from Outperform at Evercore ISI
09/12/19 H.C. Wainwright
H.C. Wainwright downgrades Tocagen with no target after 'major setback'
09/12/19 H.C. Wainwright
Tocagen downgraded to Neutral from Buy at H.C. Wainwright
Downgrade
Tocagen downgraded to Neutral from Buy at Ladenburg » 12:45
09/12/19
09/12
12:45
09/12/19
12:45
TOCA

Tocagen

$0.98 /

-3.175 (-76.41%)

Ladenburg analyst Wangzhi…

Ladenburg analyst Wangzhi Li downgraded Tocagen to Neutral from Buy after the company said the Phase 3 pivotal Toca 5 study for the treatment of recurrent high-grade gliomas missed the primary endpoint of overall survival.

ShowHide Related Items >><<
TOCA Tocagen
$0.98 /

-3.175 (-76.41%)

09/12/19 Evercore ISI
Tocagen downgraded to In Line from Outperform at Evercore ISI
09/12/19 H.C. Wainwright
H.C. Wainwright downgrades Tocagen with no target after 'major setback'
09/12/19 H.C. Wainwright
Tocagen downgraded to Neutral from Buy at H.C. Wainwright
09/12/19 Cantor Fitzgerald
Tocagen downgraded to Neutral from Overweight at Cantor Fitzgerald

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.